MDXHEALTH
MDXHNASDAQTrading Snapshot
- Day Range
- $0.51 – $0.53
- 52-Week Range
- $0.40 – $5.33
- Volume
- $2.86B
- Avg Volume
- $3.21B
- Shares Outstanding
- 51.4M
- Next Earnings
- Nov 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $108M
- Last Q Revenue
- $27M
- P/E Ratio
- -0.9
- P/S Ratio
- 0.3x
- EPS (TTM)
- $-0.58
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.4%
Why Investors Own MDXH
- ✓High-growth profile — revenue up -6.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 51% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MDXHEALTH
MDXH
StockOtter · stockotter.spaceAbout MDXHEALTH
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'
MDxHealth SA (NASDAQ:MDXH) stock skyrocketed on Friday after the diagnostic company reported mixed quarterly earnings.
MDxHealth SA (MDXH) Q2 2026 Earnings Call Transcript
MDxHealth SA (MDXH) Q2 2026 Earnings Call Transcript
MDxHealth SA (MDXH) Reports Q2 Loss, Beats Revenue Estimates
MDxHealth SA (MDXH) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.15 per share a year ago.
Mdxhealth Reports Second Quarter 2026 Financial Results
Second quarter r evenue gr owth of 1 6 % to $ 2 7 . 2 million Conference call with Q&A today at 4 : 3 0 PM EST / 22 : 30 CET
Mdxhealth to Release Second Quarter 2026 Financial Results on August 13
Company to Host Conference Call with Live Q&A, August 13, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – July 30, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today an
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency IRVINE, California – July 24, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the “Company” or “mdxhea